Search PubMed⌕ Search

Biomedical subjects

T Kajitani

Publications and source records attributed to T Kajitani.

At least 55 records · Page 3Linked to original sources

Synergism of diethylstilbestrol and other carcinogens in concurrent development of hepatic, mammary, and pituitary tumors in castrated male rats.

Castrated male WF rats, given implants of pellets containing 5.0 mg diethylstilbestrol (DES), were given N-butyl-N-nitrosourea (NBU) in small amounts, which alone produced no mammary tumors in intact female rats. Treatment resulted in the high yield of hepatic tumors (HT), mammary tumors (MT), and pituitary tumors (PT) concurrently in each rat. If animals were further treated with prolactin, the development of HT and MT was accelerated, whereas that of PT was suppressed. None of the intact or castrated rats receiving NBU and/or prolactin developed tumors in any tissues if DES treatment was omitted. Exposure of male rats, preconditioned similarly to NBU treatment, to 200 rads of 14.1-MeV fast-neutron radiation also elicited HT, MT, and PT with an efficiency comparable to that of NBU-treated rats. These findings indicate that DES played an essential role in the whole carcinogenic process in each tissue and that castrated male rats, if conditioned properly with estrogens, are useful for the study of the carcinogenesis mechanism in these tissues.

Animals↗

Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C.

A group of 496 cases was used in a controlled trial to study the possible value of mitomycin C as an adjuvant to curative surgery for gastric cancer. Patients assigned to receive the drug were given mitomycin C, 0.8 mg/kg body weight intravenously, twice a week for 5 weeks immediately after surgery. The control group was treated with surgery alone. Sixty-six patients were excluded from the study because of non-curative surgery. There was no over-all difference in survival and cancer death rates at 5 and 10 years between treated and control groups. However, a survival rate 18.6% higher at 5 years was observed in the subset of patients who had moderately advanced lymphatic metastases, and a survival rate 26.4% higher at 5 years was observed in the subset of patients who had involved serosa. The difference in cancer death rate was 14.5 and 24.0% in each subset, respectively. These significant differences persisted at 10 years. The effect of chemotherapy seemed to result from the successful inhibition of peritoneal dissemination and local recurrence. An adverse effect was observed in patients in the early stages cancer. These results suggest that mitomycin C could be useful as an adjuvant to curative surgery for moderately advanced stages of gastric cancer.

Adult↗

[Rectal cancer].

Explore the source record for details and available documents.

Humans↗